This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cancer drug developer BiPar Sciences raised $20mm through an additional financing round. Returning investors included Domain Associates, Canaan Partners, Vulcan Capital, PolyTechnos Venture-Partners, Asset Management Co., Quantum Technology Partners, and Lighthouse Capital Partners, which provided venture debt. BiPar will use the proceeds to advance its lead program BSI201 into Phase III trials for breast cancer.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?